Stefan Linsler1, Cosima Keller2, Steffi Urbschat2, Ralf Ketter2, Joachim Oertel2. 1. Klinik für Neurochirurgie, Universitätsklinikum des Saarlandes, 66421 Homburg, Saar, Germany. Electronic address: stefan.linsler@uks.eu. 2. Klinik für Neurochirurgie, Universitätsklinikum des Saarlandes, 66421 Homburg, Saar, Germany.
Abstract
OBJECTIVE: The benefit of the current strategy of diagnosis and treatment of meningiomas in contrast to the standard treatment in use before computer tomographic and magnetic resonance imaging and before the microsurgical era has not yet been determined. METHODS: Two groups of patients were compared, those on which surgery was performed before the year of 1985, when computer tomographic (CT) imaging was not yet available in our clinic and those who were treated after at the Neurosurgical Department of Saarland University. Average follow-up time was 17.9±9.3years for group 1 and 9.2±4.3years for group 2. RESULTS: The number of patients with advanced age who had surgical treatment was significantly increased in the second group, whereas the number of perioperative complications found was nearly equal in both groups (17.8% vs. 18.8%). Nevertheless, perioperative morbidity was reduced from 2.2% to 1.2%. The postoperative recurrence free time period could be revealed to be longer in the first collective (p<0.0001). Furthermore, this study shows a notable increase of the incidence of WHO grade II meningiomas in patients treated after 1985. CONCLUSIONS: Based on the presented results, the overall prognosis for patients with meningiomas has changed from the 1960s until today, since over the last two decades there has been a prolonged progression free survival time in addition to a reduced perioperative mortality rate. In the postoperative management of these patients genetic aberrations and microbiological markers should be considered as prognostic factors for meningiomas in addition to histopathological grading.
OBJECTIVE: The benefit of the current strategy of diagnosis and treatment of meningiomas in contrast to the standard treatment in use before computer tomographic and magnetic resonance imaging and before the microsurgical era has not yet been determined. METHODS: Two groups of patients were compared, those on which surgery was performed before the year of 1985, when computer tomographic (CT) imaging was not yet available in our clinic and those who were treated after at the Neurosurgical Department of Saarland University. Average follow-up time was 17.9±9.3years for group 1 and 9.2±4.3years for group 2. RESULTS: The number of patients with advanced age who had surgical treatment was significantly increased in the second group, whereas the number of perioperative complications found was nearly equal in both groups (17.8% vs. 18.8%). Nevertheless, perioperative morbidity was reduced from 2.2% to 1.2%. The postoperative recurrence free time period could be revealed to be longer in the first collective (p<0.0001). Furthermore, this study shows a notable increase of the incidence of WHO grade II meningiomas in patients treated after 1985. CONCLUSIONS: Based on the presented results, the overall prognosis for patients with meningiomas has changed from the 1960s until today, since over the last two decades there has been a prolonged progression free survival time in addition to a reduced perioperative mortality rate. In the postoperative management of these patients genetic aberrations and microbiological markers should be considered as prognostic factors for meningiomas in addition to histopathological grading.
Authors: Pearl J C van Lonkhuizen; Kete M Klaver; Jeffrey S Wefel; Margriet M Sitskoorn; Sanne B Schagen; Karin Gehring Journal: Eur J Cancer Care (Engl) Date: 2019-05-14 Impact factor: 2.328
Authors: Pearl J C van Lonkhuizen; Sophie J M Rijnen; Sophie D van der Linden; Geert-Jan M Rutten; Karin Gehring; Margriet M Sitskoorn Journal: Psychooncology Date: 2019-06-20 Impact factor: 3.894
Authors: Sophie D van der Linden; Geert-Jan M Rutten; Linda Dirven; Martin J B Taphoorn; Djaina D Satoer; Clemens M F Dirven; Margriet M Sitskoorn; Karin Gehring Journal: J Neurooncol Date: 2021-09-06 Impact factor: 4.130